Literature DB >> 19917923

Minimally invasive parathyroidectomy: use of intraoperative parathyroid hormone assays after 2 preoperative localization studies.

Nicholas Smith1, Jeffrey Scott Magnuson, David Macy Vidrine, Brian Kulbersh, Glenn E Peters.   

Abstract

OBJECTIVES: To review minimally invasive parathyroidectomy (MIP) in patients undergoing initial surgical management of primary hyperparathyroidism (HPT) with preoperative, localizing sestamibi scanning (MIBI), and concordant ultrasonography (US) to determine if intraoperative parathyroid hormone (iPTH) is necessary in these cases. Minimally invasive parathyroidectomy has become an acceptable therapeutic option in treating primary HPT. Preoperative MIBI scanning, high-resolution US with color Doppler flow, and iPTH monitoring have refined this technique.
DESIGN: Retrospective review. PATIENTS: The medical records of 738 consecutive patients who had undergone surgery for HPT. After excluding revision surgical procedures, secondary and tertiary HPT, unavailable intraoperative parathyroid (PTH) data, concomitant thyroid disease requiring thyroidectomy, and patients without preoperative MIBI or US, 428 patients (58%) were included in the study.
RESULTS: The mean decrease in PTH level was 85%. Of the 428 patients with primary HPT included in the study, 209 patients (49%) had localizing, concordant preoperative MIBI and US. A decline of more than 50% in iPTH levels was observed in 202 patients (97%) after removal of parathyroid tissue localized by MIBI and US. The procedures for 4 patients were converted to bilateral neck explorations after the postexcision PTH level failed to drop less than 50%.
CONCLUSIONS: Our results show that iPTH monitoring may be eliminated in MIP surgery in a carefully selected group of patients who have preoperative, localizing MIBI with concordant US. This potentially allows an increase in operating room efficiency and a decrease in costs while performing MIP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917923     DOI: 10.1001/archoto.2009.160

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  7 in total

1.  Endoscopic parathyroidectomy in primary hyperparathyroidism.

Authors:  Jean-Michel Prades; Alexander Asanau; Andrei P Timoshenko; Marie Gavid; Christian Martin
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-11-03       Impact factor: 2.503

2.  4D-Dynamic Contrast-Enhanced MRI for Preoperative Localization in Patients with Primary Hyperparathyroidism.

Authors:  J L Becker; V Patel; K J Johnson; M Guerrero; R R Klein; G F Ranvier; R P Owen; P Pawha; K Nael
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

3.  The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range.

Authors:  Amal Alhefdhi; Scott N Pinchot; Ruth Davis; Rebecca S Sippel; Herbert Chen
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 4.  [Intraoperative management of undetectable parathyroid adenoma].

Authors:  C Dotzenrath
Journal:  Chirurg       Date:  2015-01       Impact factor: 0.955

5.  Intraoperative PTH May Not Be Necessary in the Management of Primary Hyperparathyroidism Even with Only One Positive or Only Indeterminate Preoperative Localization Studies.

Authors:  Alireza Najafian; Stacie Kahan; Matthew T Olson; Ralph P Tufano; Martha A Zeiger
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

6.  CaPTHUS scoring model in primary hyperparathyroidism: can it eliminate the need for ioPTH testing?

Authors:  Dawn M Elfenbein; Sara Weber; David F Schneider; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2014-09-12       Impact factor: 5.344

7.  Contribution of intraoperative parathyroid hormone monitoring to the surgical success in minimal invasive parathyroidectomy.

Authors:  Ismail Ethem Akgün; Mehmet Taner Ünlü; Nurcihan Aygun; Mehmet Kostek; Mehmet Uludag
Journal:  Front Surg       Date:  2022-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.